Quantum Financial Statements From 2010 to 2026
| QNNTFDelisted Stock | USD 0.10 0.00 0.00% |
Check Quantum Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quantum Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Quantum financial statements analysis is a perfect complement when working with Quantum Genomics Valuation or Volatility modules.
Quantum |
Quantum Genomics Socit Company Return On Equity Analysis
Quantum Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Quantum Genomics Return On Equity | -1.23 |
Most of Quantum Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quantum Genomics Socit is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Quantum Genomics Socit has a Return On Equity of -1.2274. This is 94.88% lower than that of the Healthcare sector and 96.63% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Quantum Genomics Socit Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Quantum Genomics's current stock value. Our valuation model uses many indicators to compare Quantum Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quantum Genomics competition to find correlations between indicators driving Quantum Genomics's intrinsic value. More Info.Quantum Genomics Socit is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quantum Genomics' earnings, one of the primary drivers of an investment's value.About Quantum Genomics Financial Statements
Quantum Genomics stakeholders use historical fundamental indicators, such as Quantum Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Quantum Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Quantum Genomics' assets and liabilities are reflected in the revenues and expenses on Quantum Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Quantum Genomics Socit. Please read more on our technical analysis and fundamental analysis pages.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. The company was founded in 2005 and is based in Paris, France. Quantum Genomics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Quantum Pink Sheet
If you are still planning to invest in Quantum Genomics Socit check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Quantum Genomics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |